Streetbeat News

Revenues

GNRC

Generac Holdings (NYSE:GNRC) has received a range of analyst ratings over the past three months, with a notable increase in the average 12-month price target to $175.88. Analysts have shown a mix of bullish and neutral sentiments, with several raising their price targets. Despite a slight decline in revenue growth, Generac's financial metrics like net margin, ROE, and ROA remain strong, indicating effective cost management and financial health.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 6:05 pm

KVUE

Analysts have provided diverse evaluations of Kenvue (NYSE:KVUE) over the past three months, with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased to $24.1. Kenvue, a leading consumer health company, faces challenges with a slight revenue decline but maintains strong financial metrics like net margin and ROE.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 6:04 pm

CBUS

Analysts have provided mixed ratings for Cibus (NASDAQ:CBUS) over the past three months, with a majority maintaining a bullish outlook. The average 12-month price target is $21.9, slightly down from $22.00. Cibus has shown significant revenue growth but faces challenges with profitability.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 6:02 pm

RCL

Analysts have shown a positive shift in sentiment towards Royal Caribbean Gr (NYSE:RCL) over the past quarter, with several raising their price targets. The average 12-month price target has increased by 15.3% to $204.17. The company shows strong financial performance with high revenue growth and profitability, but faces challenges with high debt levels.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 6:01 pm

PFGC

Analysts have shown a positive sentiment towards Performance Food Group (NYSE:PFGC) with several raising their price targets. The average 12-month price target is now $90.11, reflecting a 5.6% increase. The company has shown revenue growth but faces challenges in net margin and ROE.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 6:01 pm

GEVO

Gevo (NASDAQ:GEVO) has been analyzed by four financial analysts, showing a range of opinions from bullish to bearish. The average 12-month price target has increased by 5.6% to $11.31. Analysts have maintained or raised their ratings, with a high target of $14.00 and a low of $3.25. Gevo's financial performance shows revenue growth but challenges in profitability and returns.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 6:01 pm

KMX

In the past three months, 16 analysts have rated CarMax (NYSE:KMX), with a mix of bullish and bearish perspectives. The average 12-month price target has increased by 1.89% to $84.12. Analysts have adjusted their ratings and price targets based on market conditions and company performance. CarMax, the largest used-vehicle retailer in the US, faces challenges with a slight revenue decline but maintains strong profitability and asset management.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 6:01 pm

PRGS

Analysts have shown a range of opinions on Progress Software (NASDAQ:PRGS) over the past quarter, with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased to $70.5, indicating positive sentiment. Progress Software has shown solid revenue growth and strong profitability, but faces challenges with its debt-to-equity ratio and return on equity.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 6:00 pm

PFE

Activist investor Starboard Value criticizes Pfizer for underperforming in R&D and overpaying for acquisitions, leading to a significant drop in stock value. Starboard highlights Pfizer's failure to meet its ambitious targets and concerns over its leveraged balance sheet, which could limit future growth.

Portfolio Pulse from Vandana Singh

October 22, 2024 | 5:55 pm

ASML

ASML Holding NV's CEO anticipates increased U.S. pressure to tighten semiconductor sales restrictions to China. ASML, which dominates lithography machines, has not sold its most advanced machines to China due to export controls. Despite potential further restrictions, ASML expects market recovery by 2025.

Portfolio Pulse from Vaishali Prayag

October 22, 2024 | 5:46 pm